These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 15082032)

  • 1. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition.
    Cattaneo C; Caccia C; Marzo A; Maj R; Fariello RG
    Clin Neuropharmacol; 2003; 26(4):213-7. PubMed ID: 12897643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers.
    Di Stefano AF; Rusca A
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):505-15. PubMed ID: 21850574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
    Müller T; Foley P
    Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.
    Krösser S; Marquet A; Gallemann D; Wolna P; Fauchoux N; Hermann R; Johne A
    Biopharm Drug Dispos; 2012 Dec; 33(9):550-9. PubMed ID: 23097240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safinamide: A Review in Parkinson's Disease.
    Blair HA; Dhillon S
    CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide (Newron Pharmaceuticals).
    Chazot PL
    Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safinamide for symptoms of Parkinson's disease.
    Müller T
    Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
    Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
    Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
    Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
    Drugs R D; 2004; 5(6):355-8. PubMed ID: 15563241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase.
    Leonetti F; Capaldi C; Pisani L; Nicolotti O; Muncipinto G; Stefanachi A; Cellamare S; Caccia C; Carotti A
    J Med Chem; 2007 Oct; 50(20):4909-16. PubMed ID: 17824599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.